This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR)

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by INC Research
Sponsor:
Collaborators:
AbbVie
Apotex Inc.
Aurobindo Pharma
Boehringer Ingelheim
Bristol-Myers Squibb
Cipla Ltd.
Hoffmann-La Roche
Gilead Sciences
Hetero Labs Ltd.
Janssen Scientific Affairs
Lupin Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Mylan Laboratories
Novartis Pharmaceuticals
Pfizer
Prinston Pharmaceutical Inc.
Ranbaxy Inc., a SunPharma Co.
Sandoz
Sciegen Pharmaceuticals Inc.
Sigmapharm Laboratories
Silarx Pharmaceuticals Inc
Strides Shasun Ltd.
Teva Pharmaceuticals USA
ViiV Healthcare
Alvogen Korea
Amneal Pharmaceuticals, LLC
West-Ward Pharmaceutical
Dr. Reddy's Laboratories UK Ltd.
Zentiva Group
Information provided by (Responsible Party):
INC Research
ClinicalTrials.gov Identifier:
NCT00404989
First received: November 27, 2006
Last updated: July 3, 2017
Last verified: July 2017
  Purpose

The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major teratogenic effect involving any of the Registry drugs when administered to pregnant women. Registration is voluntary and confidential with information obtained from the health care provider. A Registry-assigned identifier allows for follow-up capability. Information on subjects is provided to the Registry prospectively (prior to the outcome of pregnancy being known) through their health care provider, with follow-up obtained from the health care provider after the outcome is determined. Providers are strongly urged to enroll their patients as early in pregnancy as possible to maximize the validity of the data. In addition, the Registry is very interested in assembling a group of providers who are willing to make a commitment to report all of their site's antiretroviral pregnancy exposures to the Registry, thereby assuring all cases can be considered prospective. Providers are encouraged to contact the Registry for more information about this group. The Registry is informed in its analysis by other data, for example, retrospective reports and clinical studies.

Given the increasing number of medications and more aggressive approach to therapy, more HIV- and hepatitis B-infected women may be treated during pregnancy or become pregnant while under treatment. The paucity of data on use and infant outcomes of antiretroviral therapies during pregnancy makes this Registry an essential component of the ongoing program of epidemiologic studies of the safety of these therapies.

Each year the Registry has enrolled approximately 1300 pregnant women in the US exposed to antiretroviral drugs. This number represents approximately 15% of the 8,700 HIV positive women who give birth to live infants annually in the US.


Condition
HIV Infections Hepatitis B

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Antiretroviral Pregnancy Registry

Resource links provided by NLM:


Further study details as provided by INC Research:

Estimated Enrollment: 1600
Study Start Date: January 1989
Estimated Study Completion Date: January 2099
Estimated Primary Completion Date: January 2099 (Final data collection date for primary outcome measure)
Detailed Description:
The following antiretroviral drugs are followed by the Antiretroviral Pregnancy Registry (APR: Registry) to detect any major teratogenic effect when administered to pregnant women: abacavir (ZIAGEN®, ABC), abacavir/lamivudine combination (EPZICOM®, EPZ), abacavir/lamivudine/zidovudine combination (TRIZIVIR®, TZV), abacavir/dolutegravir/lamivudine combination (TRIUMEQ®, TRI), adefovir dipivoxil (HEPSERA®, ADV), amprenavir (AGENERASE®, APV), atazanavir (REYATAZ®, ATV), atazanavir/cobicistat combination (EVOTAZ®, EVO), cobicistat (TYBOST®, COBI), darunavir (PREZISTA®, DRV), darunavir/cobicistat combination (PREZCOBIX™, REZOLSTA™, PCX), delavirdine mesylate (RESCRIPTOR®, DLV), didanosine (VIDEX®, VIDEX® EC, ddI), dolutegravir (TIVICAY®, DTG), emtricitabine/ tenofovir alafenamide (DESCOVY®,DVY) efavirenz (SUSTIVA®, STOCRIN®, EFV), efavirenz/emtricitabine/ tenofovir disoproxil combination (ATRIPLA® ATR), elvitegravir (VITEKTA®, EVG), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination (GENVOYA®, GEN), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination (STRIBILD®, STB), emtricitabine (EMTRIVA®, FTC), enfuvirtide (FUZEON®, T-20), entecavir (BARACLUDE®, ETV), etravirine (INTELENCE®, ETR), fosamprenavir calcium (LEXIVA®, FOS), indinavir (CRIXIVAN®, IDV), lamivudine (EPIVIR®, 3TC), lamivudine/raltegravir combination (DUTREBIS™, DUT), lamivudine/zidovudine combination (COMBIVIR®, ZDV+3TC), lopinavir/ritonavir combination (KALETRA®, ALUVIA®, LPV/r), maraviroc (SELZENTRY®, CELSENTRI®, MVC), nelfinavir (VIRACEPT®, NFV), nevirapine (VIRAMUNE®, VIRAMUNE® XR™, NVP), raltegravir (ISENTRESS®, RAL), rilpivirine (EDURANT®, RPV), rilpivirine/emtricitabine/tenofovir alafenamide (GENVOYA®,GEN) rilpivirine/emtricitabine/tenofovir disoproxil combination (COMPLERA®, CPA; EVIPLERA®, EPA), ritonavir (NORVIR®, RTV), saquinavir (FORTOVASE®, SQV-SGC), saquinavir mesylate (INVIRASE®, SQV-HGC), stavudine (ZERIT®, d4T), telbivudine (SEBIVO®, TYZEKA®, LdT), tenofovir alafenamide (VEMLIDY®, TAF), tenofovir disoproxil fumarate (VIREAD®, TDF), tenofovir disoproxil fumarate /emtricitabine (TRUVADA®, TVD), tipranavir (APTIVUS®, TPV), zalcitabine (HIVID®, ddC), and zidovudine (RETROVIR®, ZDV). Zidovudine is indicated for use in the second and third trimesters of pregnancy to reduce the risk of maternal-fetal HIV transmission. There are also several other completed and ongoing studies in maternal-fetal transmission with other therapies. However, the safety of prenatal zidovudine or any other antiretroviral therapy exposure to the fetus has not been established.
  Eligibility

Ages Eligible for Study:   12 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Pregnant women exposed to antiviral medications during pregnancy.
Criteria

Eligibility Ages Eligible for Study: Women of childbearing age

Inclusion Criteria:

  • Country of origin of report
  • Documentation that the registry drug was taken during pregnancy
  • Sufficient information to determine if the pregnancy is being prospectively or retrospectively registered
  • Date the pregnancy was registered
  • Source of report (patient or health care provider)
  • Whether the pregnancy outcome is already known or delivery is still pending
  • Timing of the prenatal exposure to the registry medication (no broader than which trimester)
  • Sufficient patient identifier relevant to reporter to allow for follow-up
  • Was patient involved in a study at the time of prenatal exposure
  • Full reporter contact information (name, address, etc.)

Exclusion Criteria:

  • Females who were not exposed to registry medications during pregnancy
  • Male patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00404989

Contacts
Contact: Susan Goodlow 800-258-4263 SM_APR@INCResearch.com
Contact: Taylor Cook 800-258-4263 SM_APR@INCResearch.com

Locations
United States, North Carolina
Registry Coordinating Center Recruiting
Wilmington, North Carolina, United States, 28405
Sponsors and Collaborators
INC Research
AbbVie
Apotex Inc.
Aurobindo Pharma
Boehringer Ingelheim
Bristol-Myers Squibb
Cipla Ltd.
Hoffmann-La Roche
Gilead Sciences
Hetero Labs Ltd.
Janssen Scientific Affairs
Lupin Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Mylan Laboratories
Novartis Pharmaceuticals
Pfizer
Prinston Pharmaceutical Inc.
Ranbaxy Inc., a SunPharma Co.
Sandoz
Sciegen Pharmaceuticals Inc.
Sigmapharm Laboratories
Silarx Pharmaceuticals Inc
Strides Shasun Ltd.
Teva Pharmaceuticals USA
ViiV Healthcare
Alvogen Korea
Amneal Pharmaceuticals, LLC
West-Ward Pharmaceutical
Dr. Reddy's Laboratories UK Ltd.
Zentiva Group
Investigators
Principal Investigator: Jessica D Albano, PhD, MPH INC Research
  More Information

Additional Information:
Responsible Party: INC Research
ClinicalTrials.gov Identifier: NCT00404989     History of Changes
Other Study ID Numbers: APR
Study First Received: November 27, 2006
Last Updated: July 3, 2017

Keywords provided by INC Research:
HIV
HBV
Hepatitis
Pregnancy
Registry

Additional relevant MeSH terms:
Hepatitis
HIV Infections
Hepatitis B
Liver Diseases
Digestive System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Hepatitis, Viral, Human

ClinicalTrials.gov processed this record on August 23, 2017